Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Continues Positive Outlook For Migraine Treatment

Friday, September 8, 2017 12:35 PM EDT Updated: Friday, September 8, 2017 02:03 PM EDT
By Alex Brown
Lilly Continues Positive Outlook For Migraine Treatment Lilly last month detailed plans to invest $850 million into its U.S. operations this year.

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says a 12-month Phase 3 study of a migraine treatment has shown continued positive results. The pharmaceutical giant says the study for galcanezumab showed a "statistically significant reduction in the number of monthly migraine headache days" among patients.

Lilly says the treatment "demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studies." Patients received two different doses and the company says there was "no clinically meaningful difference" in the rate of adverse effects between the dosages. 

Lilly’s previously-announced plans to submit a Biologics License Application to the U.S. Food and Drug Administration remain set for the second half of 2017. The company also plans to submit to other regulatory agencies throughout the world.

"These long-term results are significant for the millions of Americans with migraine. They reinforce the efficacy and safety profile of galcanezumab while supporting its potential use as a self-administered, monthly injection," said Christi Shaw, president of Lilly Bio-Medicines. "After more than two decades of research, Lilly is excited to submit galcanezumab to the FDA as a new potential treatment option that can provide more migraine-free days for people suffering with migraine."

Lilly is presenting the results of the study at the 18th Congress of the International Headache Society in Vancouver. The company also plans to submit the findings for publication in a peer-reviewed journal "in the coming year."

The announcement comes just one day after Lilly detailed plans for a global restructuring, affecting about 3,500 employees. The company said the move will allow it to invest in the next generation of new medicines.

Story Continues Below

Most Popular Stories

  • An Angola company is making tech last longer. Its mission has led to big growth.

  • Shoe Carnival names new CFO

  • Evansville’s West Side Nut Club Fall Festival tops USA Today’s list of best fall festivals

  • Purdue to develop SARS-CoV-2 animal field test

  • Lilly to install $10M worth of solar panels at two Indy campuses

  • Indiana utilities outline outages, responses to major storms

Perspectives

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

The Indianapolis Motor Speedway has hosted countless legendary events for well over 100 years. Along with Lucas Oil Stadium, Gainbridge Fieldhouse and the Indiana Convention Center, Indianapolis hosts countless large scale, mass-gathering events. It is part of what makes this city so dynamic and special. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service